HomeCompareMAGTF vs PFE

MAGTF vs PFE: Dividend Comparison 2026

MAGTF yields 6.27% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $19.3K in total portfolio value· pulled ahead in Year 9
10 years
MAGTF
MAGTF
● Live price
6.27%
Share price
$31.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$935.40
Full MAGTF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MAGTF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMAGTFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MAGTF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MAGTF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MAGTF
Annual income on $10K today (after 15% tax)
$533.25/yr
After 10yr DRIP, annual income (after tax)
$795.09/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,524.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MAGTF + PFE for your $10,000?

MAGTF: 50%PFE: 50%
100% PFE50/50100% MAGTF
Portfolio after 10yr
$39.9K
Annual income
$13,597.06/yr
Blended yield
34.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MAGTF
Analyst Ratings
1
Buy
Consensus: Buy
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MAGTF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMAGTFPFE
Forward yield6.27%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$30.3K$49.6K
Annual income after 10y$935.40$26,258.71
Total dividends collected$7.9K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: MAGTF vs PFE ($10,000, DRIP)

YearMAGTF PortfolioMAGTF Income/yrPFE PortfolioPFE Income/yrGap
1$11,327$627.35$9,153$693.39+$2.2KMAGTF
2$12,784$664.13$8,593$849.25+$4.2KMAGTF
3$14,380$700.53$8,336$1,066.78+$6.0KMAGTF
4$16,123$736.40$8,437$1,384.80+$7.7KMAGTF
5$18,023$771.65$9,013$1,875.40+$9.0KMAGTF
6$20,091$806.16$10,306$2,680.72+$9.8KMAGTF
7$22,337$839.86$12,820$4,101.38+$9.5KMAGTF
8$24,773$872.67$17,673$6,826.70+$7.1KMAGTF
9← crossover$27,412$904.54$27,543$12,591.86$131.00PFE
10$30,266$935.40$49,560$26,258.71$19.3KPFE

MAGTF vs PFE: Complete Analysis 2026

MAGTFStock

Magnet Forensics Inc., together with its subsidiaries, engages in the development of data analytics software used for digital forensics investigations to public sector and private enterprises in Canada, the United States, Australia, and Europe. It offers Magnet AXIOM, a digital investigations platform to recover analyze, and report on digital evidence from smartphones, cloud services, IoT devices, and third-party images; Magnet AXIOM CYBER, a digital forensics and incident response solution for businesses that need to perform remote acquisitions, and collect and analyze evidence from computers, cloud, and mobile devices; and Magnet OUTRIDER, a digital evidence triage tool used at crime scenes to scan digital media for the presence of CSAM. The company also provides Magnet AUTOMATE, an orchestration and automation tool to enable law enforcement agencies to create automated and repeatable digital evidence processing workflows; Magnet REVIEW to securely share the digital evidence via a single web-based platform; Magnet ATLAS, a workflow orchestration tool to manage cases, generate real-time reports, and track digital investigations; Magnet Digital Investigation Suite that transform digital investigations with analytics and collaborate agency-wide, securely, and at scale; and Magnet IGNITE, a cloud-based early case assessment triage tool. It serves large government agencies, corporations, and professional services firms. The company was formerly known as JADsoftware Inc. and changed its name to Magnet Forensics Inc. in August 2012. Magnet Forensics Inc. was incorporated in 2010 and is headquartered in Waterloo, Canada.

Full MAGTF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MAGTF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MAGTF vs SCHDMAGTF vs JEPIMAGTF vs OMAGTF vs KOMAGTF vs MAINMAGTF vs JNJMAGTF vs MRKMAGTF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.